Forxiga® - Diabetes

General information

The Reimbursement Solution TerugBetaalRegeling (TBR) of Forxiga® (dapagliflozine) 10 mg for patients with diabetes type 2, WITHOUT a very high risk of cardiovascular disease AND who are not eligible for the pre-existing reimbursement of the health insurer (in combination with metformin and/or SU), will be continued. The end date for this TBR for this group of patients has not yet been determined.

Type 2 diabetes patients WITH a very high risk on cardiovascular disease are covered by the regular reimbursement of the health insurance. Very high risk is defined as:
• established cardiovascular disease; and/or
• chronic kidney disease with

− eGFR 30-44 ml/min/1,73 m2 without albuminuria or
− eGFR 30-59 ml/min per 1.73m2 with moderately elevated albuminuria (ACR > 3 mg/mmol/l); or
− eGFR ≥ 60 ml/min per 1.73 m2 with severely elevated albuminuria (ACR > 30 mg/mmol)

^{(NL-8733. Prod 02.2022)}

For a complete reimbursment overview of Forxiga® (dapagliflozine) 10 mg, clickhere. 

For a digital reimbursement guide of Forxiga® (dapagliflozine) 10 mg, click here.